Quantcast
Last updated on April 23, 2014 at 1:22 EDT

Latest Placebo-controlled study Stories

2012-07-14 23:00:02

The first double-blind, placebo-controlled trial using bulbine natalensis extract, ProLensis, found to be safe in humans. New York, New York (PRWEB) July 14, 2012 Sports Nutrition Research, purveyors of the testosterone-boosting compound ProLensis, has announced that a human safety study using the extract is to be published. Bulbine natalensis is a plant indigenous to Africa, traditionally used as an aphrodisiac and tonic in tribesmen. ProLensis is a well-studied specific extract of bulbine...

2012-07-06 23:00:22

There are countless articles online about the purported benefits of cayenne and capsaicin. Natural Health Sherpa investigated and went through scientific studies and published what they found. Wilmington, NC (PRWEB) July 06, 2012 While capsaicin in cayenne is associated with numerous health benefits such as fighting diabetes, weight loss, and even fighting cancer, Natural Health Sherpa found out that scientific evidence shows that it is most useful in treating pain. “The strongest...

2012-06-27 14:22:05

HAYWARD, Calif., June 27, 2012 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation and autoimmune disorders, today announced results from the Phase 2b PEARL-SC clinical study in patients with systemic lupus erythematosus. The purpose of the PEARL-SC study was to identify an effective and safe dose for future phase 3 clinical studies and explore key inclusion criteria and clinical...

2012-06-13 02:26:49

IRVINE, Calif., June 13, 2012 /PRNewswire/ -- ChromaDex Corporation (OTCBB: CDXC), an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, animal health, cosmetic and pharmaceutical industries announced today its patented pTeroPure (pterostilbene) was shown to be safe for human consumption according to data from the first clinical trial of the substance. The findings, based on a study...

2012-06-06 02:24:50

SAN DIEGO and ATLANTA, June 6, 2012 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, and Sharecare® an interactive health and wellness social platform providing people with access to expert-developed answers, information and programs to live their healthiest life, announce their partnership for WeightMate(TM), a comprehensive weight management program developed for participants in the Light Study. Delivered...

2012-06-03 18:20:47

SOUTH SAN FRANCISCO, Calif., June 4, 2012 /PRNewswire/ -- Onyx Pharmaceuticals (Nasdaq: ONXX) today announced data from the Phase 3 GRID (GIST - Regorafenib In Progressive Disease) trial evaluating the investigational drug regorafenib, a Bayer compound, in patients with metastatic and/or unresectable gastrointestinal stromal tumors (GIST) whose disease had progressed despite prior treatment with imatinib and sunitinib. The GRID study met its primary endpoint of progression-free survival (PFS)...

2012-06-03 18:20:41

WAYNE, N.J., June 4, 2012 /PRNewswire/ -- Bayer HealthCare today announced data from the Phase III GRID (GIST - Regorafenib In Progressive Disease) trial evaluating its investigational drug regorafenib in patients with metastatic and/or unresectable gastrointestinal stromal tumors (GIST) whose disease had progressed despite prior treatment with imatinib and sunitinib. The GRID study met its primary endpoint of improvement in progression-free survival (PFS) (HR=0.27, p<0.0001).(1) The...

2012-05-31 11:58:10

The American Medical Association's Code of Ethics prohibits physicians from prescribing treatments that they consider to be placebos unless the patients know this and agree to take them anyway. But this policy is not clearly the best way to protect or benefit patients, concludes an The American Medical Association's Code of Ethics prohibits physicians from prescribing treatments that they consider to be placebos unless the patients know this and agree to take them anyway. But this policy is...

2012-05-30 02:25:31

MONMOUTH JUNCTION, N.J., May 30, 2012 /PRNewswire/ -- Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, today provided a corporate update, including the Company's current strategic development priorities for ARIKACE® (liposomal amikacin for inhalation). "Insmed has determined that its current resources will be applied towards the CLEAR-108 phase 3 European and Canadian registrational study of ARIKACE in patients with Cystic Fibrosis (CF)-related Pseudomonas aeruginosa...

2012-05-23 02:26:29

MONMOUTH JUNCTION, N.J., May 23, 2012 /PRNewswire/ -- Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, today announced that it has begun screening patients for its U.S. phase 2 clinical trial, Treatment with ARIKACE to Realize Greater Efficacy Trial (TARGET-NTM), of ARIKACE® (liposomal amikacin for inhalation) in patients with non-tuberculous mycobacterial (NTM) lung disease. There have been very few clinical trials to support current NTM treatment recommendations,...